Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland

CompletedOBSERVATIONAL
Enrollment

112

Participants

Timeline

Start Date

September 12, 2018

Primary Completion Date

March 26, 2019

Study Completion Date

March 26, 2019

Conditions
Chronic Lymphocytic Leukaemia
Interventions
DRUG

Idelalisib

Tablets were administered in accordance with the marketing authorization.

DRUG

Rituximab

Tablets were administered in accordance with the marketing authorization.

Trial Locations (16)

8

St James Hospital, Dublin

AB25 2ZN

NHS Grampian, Aberdeen

CF14 4XW

University Hospital of Wales, Cardiff

GL53 7AN

Cheltenham General Hospital, Cheltenham

HA4 8PD

London Northwest University NHS Trust, Eastcote

ME7 5NY

Medway Maritime Hospital, Gillingham

HA1 3UJ

Queen Alexandra Hospital, Harrow

SE5 9RS

King's College Hospital NHS Foundation Trust, London

MK6 5LD

Milton Keynes University Hospital, Milton Keynes

OX3 7LE

Oxford University Hospitals NHS Trust, Oxford

L35 5DR

Whiston Hospital - St Helens And Knowsley Teaching Hospitals NHS Trust, Prescot

SS0 0RY

Southend University Hospital NHS Foundation Trust, Southend-on-Sea

SM2 5PT

Royal Marsden Hospital, Sutton

SA2 8QA

Singleton Hospital, Swansea

TR1 3LJ

Royal Cornwall Hospital, Truro

WR5 1DD

Worcestershire Royal Hospital, Worcester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY